Four key presentations at last week's American Society of Clinical Oncology meeting spotlighted the pace at which the next wave of cancer immunotherapies are building a case to supplant Yervoy ipilimumab.

Immune checkpoint inhibitors from Bristol-Myers Squibb Co., Merck & Co. Inc. and Roche, and an oncolytic virus from Amgen Inc., all showed better tumor responses in melanoma than BMS's Yervoy, the first immunotherapy to show an overall survival benefit in that cancer.